Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Barclays PLC

Barclays PLC cut its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 82.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 169,195 shares of the company’s stock after selling 812,691 shares during the period. Barclays PLC’s holdings in Syndax Pharmaceuticals were worth $3,541,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Point72 Hong Kong Ltd bought a new stake in Syndax Pharmaceuticals in the 1st quarter valued at about $41,000. Royal Bank of Canada lifted its position in Syndax Pharmaceuticals by 1,144.7% in the 3rd quarter. Royal Bank of Canada now owns 3,622 shares of the company’s stock valued at $87,000 after purchasing an additional 3,331 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Syndax Pharmaceuticals by 23.1% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,832 shares of the company’s stock valued at $102,000 after purchasing an additional 907 shares during the last quarter. Sandia Investment Management LP bought a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $127,000. Finally, Exchange Traded Concepts LLC lifted its position in Syndax Pharmaceuticals by 740.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 7,213 shares of the company’s stock valued at $151,000 after purchasing an additional 6,355 shares during the last quarter.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX opened at $13.55 on Monday. The company’s 50 day simple moving average is $14.50 and its 200 day simple moving average is $18.33. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.22 and a 12 month high of $29.86. The company has a market capitalization of $943.64 million, a P/E ratio of -5.25 and a beta of 1.04.

Wall Street Analyst Weigh In

SNDX has been the topic of several recent research reports. The Goldman Sachs Group assumed coverage on shares of Syndax Pharmaceuticals in a research report on Wednesday, October 11th. They issued a “buy” rating and a $30.00 price objective on the stock. Guggenheim boosted their price target on shares of Syndax Pharmaceuticals from $42.00 to $43.00 in a research report on Tuesday, October 3rd. B. Riley boosted their price target on shares of Syndax Pharmaceuticals from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 25th. StockNews.com assumed coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 5th. They set a “sell” rating on the stock. Finally, Stifel Nicolaus dropped their price target on shares of Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.09.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).